US1856341029 - Common Stock
CLENE INC
NASDAQ:CLNN (5/2/2024, 5:01:04 PM)
After market: 0.432 0 (-1.08%)0.4367
0 (-0.07%)
Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutics for neurodegenerative diseases. The company is headquartered in Salt Lake City, Utah and currently employs 75 full-time employees. The company went IPO on 2018-08-27. The firm is focused on treatment of neurodegenerative disease by targeting energetic failure, an underlying cause of many neurological diseases. Its drug candidate, CNM-Au8, is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy production and utilization. The catalytically active nanocrystals of CNM-Au8 drive critical cellular energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors. Its other products include CNM-ZnAg and CNM-AgZn17. CNM-ZnAg is a spectrum antiviral, antibacterial agent comprised of zinc and silver ions under development to treat infectious disease and to provide immune support for symptom resolution. CNM-AgZn17 is a gel polymer suspension of zinc and silver under development for treatment of infectious diseases and to support wound healing.
CLENE INC
6550 South Millrock Drive, Suite G50
Salt Lake City UTAH 84121
P: 18016769695
CEO: Robert Etherington
Employees: 75
Website: https://clene.com/
It's time to dive into the biggest pre-market stock movers with all of the hottest news worth reading about on Wednesday!
Long term extension of the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 demonstrated significant evidence of repair and remyelination across multiple...
Penny stocks are incredibly risky. However, if you can handle the heat, these ideas might be worth your while.
Proprietary catalytic gold nanocrystals comprising Clene’s investigational drug CNM-Au8® develop a protein corona upon exposure to human blood plasma...
Initiated discussions with FDA regarding accelerated approval pathway for CNM-Au8® for the treatment of ALS with the objective of submitting an NDA in...
Long-term CNM-Au8 treatment demonstrated significant and clinically meaningful improvement of vision as measured by low contrast letter acuity (LCLA), an...
Here you can normally see the latest stock twits on CLNN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: